Ainewsbreaks Lantern Pharma (NASDAQ: LTRN) Reports Q2 2025 Results, Achieves Complete Responses In Multiple Trials, Expands AI Platform

(MENAFN- Investor Brand Network) Lantern Pharma (NASDAQ: LTRN) , a clinical-stage biopharma company leveraging its RADR(R) AI/ML platform for oncology drug discovery and development, announced Q2 2025 results and portfolio updates. The company reported complete responses in patients across two trials - LP-300 in advanced NSCLC and LP-284 in refractory diffuse large B-cell lymphoma - along with completion of LP-184 Phase 1a enrollment, positioning it for Phase 1b/2 studies in high-value indications. LP-184 has FDA Fast Track and multiple Rare Pediatric Disease designations and showed significant survival gains in ATRT models. Lantern strengthened its IP with a European patent allowance for LP-284 and publication of a PCT application for its predictBBB(TM) AI module. RADR(R) enhancements included the public launch of predictBBB(TM) and a new drug combination prediction module. Q2 R&D expenses fell to $3.1 million from $3.9 million a year ago, G&A was $1.6 million versus $1.5 million, and net loss narrowed to $4.33 million from $4.96 million. Cash, equivalents, and marketable securities totaled $15.9 million at quarter-end, funding operations into June 2026.

To view the full press release, visit

About Lantern Pharma

Lantern Pharma (NASDAQ: LTRN) is an AI company transforming the cost, pace, and timeline of oncology drug discovery and development. Our proprietary AI and machine learning (ML) platform, RADR(R), leverages over 200 billion oncology-focused data points and a library of 200+ advanced ML algorithms to help solve billion-dollar, real-world problems in oncology drug development. By harnessing the power of AI and with input from world-class scientific advisors and collaborators, we have accelerated the development of our growing pipeline of drug candidates that span multiple cancer indications, including both solid tumors and blood cancers and an antibody-drug conjugate (ADC) program. On average, our newly developed drug programs have been advanced from initial AI insights to first-in-human clinical trials in 2-3 years and at approximately $1.0 – 2.5 million per program.

NOTE TO INVESTORS: The latest news and updates relating to LTRN are available in the company's newsroom at

About AINewsWire

AINewsWire (“AINW”) is a specialized communications platform with a focus on the latest advancements in artificial intelligence (“AI”), including the technologies, trends and trailblazers driving innovation forward. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers : (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries ; (2) article and editorial syndication to 5,000+ outlets ; (3) enhanced press release enhancement to ensure maximum impact ; (4) social media distribution via IBN to millions of social media followers ; and (5) a full array of tailored corporate communications solutions . With broad reach and a seasoned team of contributing journalists and writers, AINW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists, and the general public. By cutting through the overload of information in today's market, AINW brings its clients unparalleled recognition and brand awareness.

AINW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from AINewsWire, text“AI” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit

Please see full terms of use and disclaimers on the AINewsWire website applicable to all content provided by AINW, wherever published or re-published: imer, Texas

512.354.7000 Office
href="/cdn-cgi/l/email-protection#70351419041f023031393e150703271902155e131f1d" target="_blank" rel="noreferrer noopener">[email protected]

AINewsWire is powered by IBN

MENAFN14082025000224011066ID1109930299